Prognostic factors affecting survival in malignant pleural mesothelioma: Analysis of 125 subjects

Tumori

Volumn 100, Issue 1, 2014, Pages 55-59

  Komurcuoglu, Berna ^a   Cirak, A Kadri ^a   Kirakli, S Cenk ^a   Polat, Gulru ^a   Yucel, Nur ^a   Usluer, Ozan ^a   Erer, Onur ^a   Balci, Gunseli ^a   Gayaf, Mine ^a   Guldaval, Filiz ^a   Aktogu, Serir ^a   Guclu, Salih ^a   Ozsoz, Ayse ^a   Halilcolar, Huseyin ^a  

^a Respiratory Medicine Mesothelioma Study Group of Izmir Dr Suat Seren Respiratory Diseases and Thoracic Surgery Training and Research Hospital   (Turkey)

Author keywords

Malignant pleural mesothelioma; Prognostic factors; Survival

Indexed keywords

LACTATE DEHYDROGENASE;

ADULT; AGE; AGED; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISTANT METASTASIS; ENZYME BLOOD LEVEL; FEMALE; GENDER; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LEUKOCYTE; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; PLEURA MESOTHELIOMA; SMOKING; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTE; YOUNG ADULT;

AGE FACTORS; AGED; ASBESTOS; ENVIRONMENTAL EXPOSURE; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MESOTHELIOMA; MIDDLE AGED; NEOPLASM STAGING; PLEURAL NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SEX FACTORS; SMOKING; TURKEY;

EID: 84896931297     PISSN: 03008916     EISSN: 20382529     Source Type: Journal    
DOI: 10.1177/1430.15816     Document Type: Article

References (25)

1. Robinson BW, Musk AW, Lake RA: Malignant mesothelioma. Lancet, 366-408, 2005.
2. Scherpereel A, Astoul P, Baas P, Berghmans T, Clayson H, de Vuyst P, Dienemann H, Galateau-Salle F, Hennequin C, Hillerdal G, Le Pe'choux C, Mutti L, Pairon JC, Stahel R, van Houtte P, van Meerbeeck J, Waller D, Weder W: ERS/ETS task force. Guidelines of European Respiratory Society and the European Society of Thoracic Surgeons for management of malignant pleural mesothelioma. Eur Respir J, 35: 479-495, 2010.
3. Stahel RA, Weder W, Felip E: Malignant pleural mesothelioma: ESMO clinical reccommendations for diagnosis, treatment and follow up. Ann Oncol, 19: 43-44, 2008.
4. Nicholson NJ, Perkel G, Selikoff IJ: Occupational exposure to asbestos; population at risk and project mortality 1980-2030. Am J Intern Med, 3: 259-311, 1982.
5. Zeren EH, Gümürdülü D, Roggli VL, Tuncer I, Zorludemir S, Erkii M: Enviromental malignant mesothelioma in southern Anatolia: A study of fifty cases. Environ Health Persoec, 108: 1047-1050, 2000.
6. Peto J, Hodgson JT, Matthews FE, Jones JR: Continuing increase in malignant mesothelioma mortality in Great Britain. Lancet, 345: 535-539, 1995.
7. Van Meerbeek JP, Gaafar R, Manegold C, Van Klaveren RJ, Van Marck EA, Vincent M, Legrand C, Bottomley A, Debruyne C, Giaccone G: Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol, 23: 6881-6689, 2005.
8. Ellis P, Davies AM, Evans WK, Haynes AE, Lloyd NS: The use of chemotherapy in patients with advanced malignant pleural mesothelioma: A systemic review and practice guideline. J Thorac Oncol, 1: 591-601, 2006.
9. Garland LL: Chemotherapy for malignant pleural mesothelioma. Current Treatment Options Oncol, 12: 181-188, 2011.
10. Rusch VW: A proposed new international TNM staging system for malignant pleural mesothelioma from the International Mesothelioma Interest Group. Lung Cancer, 14: 1-12, 1996.
11. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol, 5: 649-655, 1982.
12. Rusch VW, Giroux D, Kennedy C, Ruffini E, Cangir AK, Rice D, Pass H, Asamura H, Waller D, Edwards J, Weder W, Hoffmann H, van Meerbeeck JP: Initial analysis of the International Association For the Study of Lung Cancer Mesothelioma Database. J Thorac Oncol, 7: 1631-1639, 2012.
13. Sugarbaker DJ, Flores RM, Jaklitsch MT, Richards WG, Strauss GM, Corson JM, DeCamp MM Jr, Swanson SJ, Bueno R, Lukanich JM, Baldini EH, Mentzer SJ: Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg, 117: 54-63, 1999.
14. Van Gelder T, Damhulis RAM, Hoogsteden HC: Prognostic factors and survival in malignant pleural mesothelioma. Eur Respir J, 7: 1035-1038, 1994.
15. Metintas M, Ucgun I, Harmanc E, Alata E, Erginel S: Prognostic factors in diffuse malignant pleural mesothelioma: effects of pretreatment clinical and laboratory characteristics. Respir Med, 95: 829-835, 2001.
16. Ak G, Metinta S, Metintas M, Yldrm H, Erginel S, Kurt E, Alatas F, Cadrc O: Prognostic factors according to the treatment schedule in malignant pleural mesothelioma. J Thorac Oncol, 4: 1425-1430, 2009.
17. Ruffie P, Feld R, Minkin S, Cormier Y, Boutan-Laroze A, Ginsberg R, Ayoub J, Shepherd FA, Evans WK, Figueredo A: Diffuse malignant mesothelima of the plevra in Ontario and Quebec: a retrospective study of 322 patients. J Clin Oncol, 7: 1157-1168, 1989.
18. Curran D, Sahmoud T, Therasse P, van Meerbeeck J, Postmus PE, Giaccone G: Prognostic factors in patients with pleural mesothelioma: The European Organization for Resarch and Treatment of Cancer Experiance. J Clin Oncol, 16: 145-152, 1998.
19. Herndon JE, Green MR, Chahinian, Corson JM, Suzuki Y, Vogelzang NJ: Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by Cancer and Leukemia Group B. Chest, 113: 723-731, 1998.
20. Antman KH, Shemin R, Ryan L, Antman K, Shemin R, Ryan L, Klegar K, Osteen R, Herman T, Lederman G, Corson J: Malignant mesothelioma; prognostic variables in a registry of 180 patients, the Dana-Farber Cancer Institute and Brigham and Women's Hospital experience over two decades, 1965-1985. J Clin Oncol, 6: 147-153, 1998.
21. Chahinian AP, Pajak TF, Holland JF, Norton L, Ambinder RM, Mandel EM: Diffuse malignant mesothelioma. Prospective evaluation of 69 patients. Ann Intern Med, 96: 746-755, 1992.
22. Hillerdal G: Staging and evaluating responses in malignant pleural mesothelioma. Lung Cancer, 43: 75-76, 2004.
23. Barbieri PG, Marinaccio A, Ferrante P, Scarselli A, Pinelli V, Tassi G: Effects of combined therapies on the survival of pleural mesothelioma patients treated in Brescia, 1982-2006. Tumori, 98: 215-219, 2012.
24. Francart J, Vaes E, Henrard S, Legrand C, Baas P, Gaafar R, Meerbeeck JP, Sylvester R, Robert A: A prognostic index for progression-free survival in malignant mesotelioma with application to design of phase II trials: a combined analysis of 10 EQRTC trials. Eur J Cancer, 45: 2304-2311, 2009.
25. Metintas M, Ak G, Erginel S, Alatas F, Yildirim H, Kurt E, Metintas S: A retrospective analysis of malignant mesothelioma patients treated either with chemotherapy and BSC between 1990 and 2005: a single instutition experience. Lung cancer, 55: 379-387, 20